Efficacy and safety of Garenoxacin for the prevention in the patients with hematological malignancies after chemotherapy
Phase 2
- Conditions
- hematological malignancies
- Registration Number
- JPRN-UMIN000004979
- Lead Sponsor
- Gifu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)GRNX is obviously ineffective to the pathogen. 2)Patients with a history of allergy/severe adverse effect to quinolone antibacterial agents or garenoxacin 3)Allergic diathesis 4)Pregnancy/lactation 5)Age of 15 years or younger 6)Patient was received systemic antibacterial therapy within 14 days 7)Patients who are regarded as inadequate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method